Companies
Hengrui Medicine
transitioning its massive legacy pharma portfolio heavily toward innovative large-molecule biologics.
- Country
- China
- Ticker
- 600276.SS
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | US$1.27 billion from HKEX IPO (2025) | pharmaboardroom.com · hengrui.com · hkexnews.hk · www1.hkexnews.hk |
| Capacity | Multiple ongoing capacity expansion projects including mRNA, plasmid, and API production lines across various industrial parks medium confidence | hengrui.com · hkexnews.hk · www1.hkexnews.hk |
| Certification | Designated as Environmental Protection Model Enterprise, Green Development Leader, and Sterile Drug Quality Assurance Enterprise | futunn.com · hengrui.com |
| Regulatory approval | 26 Class 1 and 6 Class 2 innovative drugs approved for marketing in China as of August 2026 | hkexnews.hk · www1.hkexnews.hk |
| Production site | Manufacturing facilities in Lianyungang (Dapu and Lingang Industrial Parks), Guangzhou, and Beijing | futunn.com · hengrui.com |
| Headcount | Over 5,600 R&D professionals and ~9,000 commercial staff | hengrui.com · hkexnews.hk |
| Revenue | RMB15,455.6 million for the first half of 2026 | hkexnews.hk · www1.hkexnews.hk |
Independent sources: futunn.com · hkexnews.hk · pharmaboardroom.com · www1.hkexnews.hk
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biopharmaceuticals & biomedicines | therapeutics-platforms | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.